Afficher la notice abrégée

Iodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro

dc.rights.licenseopenen_US
hal.structure.identifierCentre de résonance magnétique des systèmes biologiques [CRMSB]
dc.contributor.authorDALLAUDIERE, Benjamin
dc.contributor.authorCROMBE, Amandine
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorGADEAU, Alain-Pierre
dc.contributor.authorPESQUER, Lionel
dc.contributor.authorPEUCHANT, A.
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorJAMES, Chloe
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorSILVESTRE, Armando
dc.date.accessioned2020-11-17T08:47:09Z
dc.date.available2020-11-17T08:47:09Z
dc.date.issued2018-10
dc.identifier.issn2197-1153en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/14050
dc.description.abstractEnBACKGROUND: Iodine contrast agents (ICAs) are routinely used by radiologists to help guide intra-articular infiltrations. The aim of this study was to assess the in vitro effects of ICA on platelet function of human autologous Platelet-Rich Plasma (PRP). METHODS: One hundred thirty-seven consecutive patients with symptomatic femoral-patellar osteoarthritis were included. All were addressed to our institution for a fluoroscopy-guided intra-articular PRP infiltration of the pathological femoral-patellar joint. For each patient, 500 μl of PRP were sampled before intra-articular injection. First, PRP samples were mixed with 50 μl of 2 widely used ICA: Visipaque270® (Iodixanol, n = 58) and Iopamiron200® (Iopamidol, n = 69). PRP concentration ([PRP]) was measured at different delays of incubation (t = 0, 5, 10, 15, 20 and 30 min) enabling to calculate PRP ratio (defined as [PRP](t)/[PRP](0mn)) at each delay, for each mixture, in order to quantitatively assess the influence of ICA on PRP ratio. Second, the PRP samples of 10 additional patients were mixed with Visipaque270®, Visipaque270®, Iopamiron200® and phosphate buffer saline (PBS: control solution) in order to qualitatively assess the influence of ICA on platelet aggregation, using ADP, Collagen, Arachidonic acid and TRAP tests. The surface expression of human P-selectin, a marker of α-granule release, in the PRP + Visipaque270® and PRP + Iopamiron200® mixtures was finally compared. Repeated-measures ANOVA, classical 2-way ANOVA and Wilcoxon matched-pairs test were used to study the influence of ICA on PRP quality. RESULTS: There was no significant change in PRP ratio during the first 30mn of incubation (p = 0.991) whatever the ICA (p = 0.926). Whatever the aggregation test, there was no significant difference in the percentage of platelet aggregation between PRP + PBS, PRP + Visipaque270® and PRP + Iopamiron200® (p = 0.998), nor between PRP + PBS and PRP + Visipaque320® (p = 0.470). Finally, there was no significant difference in P-selectin expression between the PRP + Visipaque270® and PRP + Iopamiron200® mixtures (p = 0.500). CONCLUSION: At early delays of incubation, Visipaque® and Iopamiron®, which are two widely used ICA for intra-articular infiltrations, did not influence the in vitro platelet function nor the quality of PRP.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/
dc.subjectArticle RECHERCHE
dc.subject.enArthritis
dc.subject.enIntra-articular infiltration
dc.subject.enLodine contrast agent
dc.subject.enPlatelet
dc.title.enIodine contrast agents do not influence Platelet-Rich Plasma function at an early time point in vitro
dc.typeArticle de revueen_US
dc.identifier.doi10.1186/s40634-018-0162-4en_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed30374787en_US
bordeaux.journalJournal of Experimental Orthopaedicsen_US
bordeaux.page47en_US
bordeaux.volume5en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires - U1034en_US
bordeaux.issue1en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRS
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Journal%20of%20Experimental%20Orthopaedics&rft.date=2018-10&rft.volume=5&rft.issue=1&rft.spage=47&rft.epage=47&rft.eissn=2197-1153&rft.issn=2197-1153&rft.au=DALLAUDIERE,%20Benjamin&CROMBE,%20Amandine&GADEAU,%20Alain-Pierre&PESQUER,%20Lionel&PEUCHANT,%20A.&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
BMC_JExpOrthop_2018_Dallaudiere.pdf
Taille:
1.474Mo
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée